文献速递白血病造血干细胞移植与细胞治疗

达沙替尼联合多药化疗方案治疗初诊Ph阳性急性淋巴细胞白血病的前瞻性单中心研究

[Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2021-01-01

该前瞻性单臂开放临床研究纳入30例初诊成人Ph阳性急性淋巴细胞白血病患者,采用达沙替尼联合多药化疗方案。所有患者诱导后达血液学完全缓解,累积完全分子学反应率70.0%,3年总生存率68.1%,3年无血液学复发生存率61.6%,方案安全有效。

要点

  • 达沙替尼联合多药化疗在初诊成人Ph阳性ALL中安全有效。
  • 6个月内达到完全分子学反应者总生存、无血液学复发生存及无事件生存更优。
  • 移植组无血液学复发生存和无事件生存优于化疗组。

核心结论

  • 达沙替尼联合多药化疗方案治疗初诊成人Ph阳性ALL安全有效。

研究设计与样本

  • 前瞻性、单臂、开放临床研究,纳入2016年1月至2018年4月单中心收治的30例初诊成人Ph阳性ALL患者。
  • 标准诱导化疗4周,自诱导第8天起口服达沙替尼100 mg/d持续至整体治疗结束。
  • 有条件和意愿者可行异基因或自体造血干细胞移植。

主要发现

  • 30例患者诱导治疗4周后均达血液学完全缓解,累积完全分子学反应率70.0%(21/30)。
  • 中位随访37.8(32.0~46.6)个月,3年总生存率68.1%,3年无血液学复发生存率61.6%。
  • 63.3%患者在治疗3个月时达主要分子学反应,其中43.3%达完全分子学反应。
  • 6个月时60.0%患者达完全分子学反应,达者总生存(P=0.004)、无血液学复发生存(P=0.049)和无事件生存(P=0.001)更优。
  • 15例(50.0%)患者在第1次血液学完全缓解期内移植,移植组无血液学复发生存(P=0.030)和无事件生存(P=0.010)优于化疗组。

临床怎么用

  • 初诊成人Ph阳性ALL可考虑达沙替尼联合多药化疗作为诱导及整体治疗方案。
  • 治疗早期(6个月内)达完全分子学反应者预后更优,应重视分子学反应监测。
  • 首次血液学完全缓解期有条件者可行造血干细胞移植,移植组无血液学复发生存和无事件生存更优。

局限性

  • 单中心、单臂、开放设计,样本量30例,无随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study evaluates the efficacy and safety of dasatinib combined with a multi-agent chemotherapy regimen of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) patients. Methods: This prospective, single-arm, and open clinical study enrolled 30 adult Ph(+) ALL patients who were newly diagnosed and treated from January 2016 to April 2018 in the center of this study. Standard induction chemotherapy was given for 4 weeks. However, dasatinib (100 mg/d) was continuously administered from day 8 until the end of the whole therapy in the induction therapy. Patients who are available for allogeneic or autologous stem cell transplantation (SCT) received transplantation when the disease was evaluated as complete remission. Results: All 30 patients achieved hematological complete remission (HCR) after the induction chemotherapy, and 70.0% (21/30) of them achieved the accumulated molecular complete remission (MCR) . The patients were followed up with a median follow-up time of 37.8 months (32.0-46.6) . The 3 year overall survival (OS) and 3 year hematological relapse-free survival (HRFS) were 68.1% and 61.6%, respectively. Moreover, 63.3% and 43.3% of the patients achieved molecular major remission and MCR, respectively. Consequently, 60.0% of the patients achieved MCR until 6 months. The patients who achieved MCR within 6 months had superior OS (P=0.004) , HRFS (P=0.049) , and event-free survival (EFS; P=0.001) . Fifteen patients (50.0%) received SCT at the first HCR. However, HRFS (P=0.030) and EFS (P=0.010) in the SCT group were better than those in the chemotherapy group. Conclusions: The regimen of dasatinib combined with a multi-agent chemotherapy was proven safe and effective in the treatment of newly diagnosed adult Ph(+) ALL patients. Clinical trial registration: ClinicalTrials.gov, NCT02523976. 目的: 评价达沙替尼联合多药化疗方案在Ph染色体阳性急性淋巴细胞白血病(Ph(+) ALL)患者中的疗效及安全性。 方法: 前瞻性、单臂、开放的临床研究。2016年1月至2018年4月中国医学科学院血液病医院收治的30例初诊成人Ph(+) ALL患者入组。采用多药化疗方案,标准诱导化疗为期4周,自诱导化疗第8天开始口服达沙替尼(商品名依尼舒,正大天晴药业集团股份有限公司产品)100 mg/d,持续应用至整体治疗结束。有条件和意愿进行移植者,可进行异基因造血干细胞移植或自体造血干细胞移植。 结果: 所有30例患者在诱导治疗4周后均达到血液学完全缓解(HCR),累积完全分子学反应(MCR)率为70.0%(21/30)。中位随访时间为37.8(32.0~46.6)个月。3年总生存(OS)率为68.1%,3年无血液学复发生存(HRFS)率为61.6%。63.3%的患者在治疗3个月时达到主要分子学反应(MMR)(其中有43.3%患者达到MCR)。6个月时60.0%的患者达到MCR,达到MCR的患者具有更好的OS(P=0.004)、HRFS(P=0.049)和EFS(P=0.001)。15例(50.0%)患者在第1次HCR期内进行移植,移植组患者HRFS(P=0.030)和EFS(P=0.010)优于化疗组。 结论: 达沙替尼联合多药化疗方案治疗初诊Ph(+)ALL安全有效。 临床试验注册: ClinicalTrials.gov,NCT02523976。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang GJ, Gong XY, Qiu SW, et al. [Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33858040. doi:10.3760/cma.j.issn.0253-2727.2021.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。